All products

AstraZeneca receives regulatory boost for...

AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

Top 7 Trends In Pharmaceutical Research I...

Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

ARS-1620: A promising new inhibitor for K...

According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

All products

CPDD1843

CAS:Free1217651-75-6,MSC2530818 Intermediate

CPDD1840

CPDD0277

GDC-0326

OTS964

GSK-461364

Quizartinib; AC-010220; AC-220

AZD9496

DEL-22379

AZD8186

Vactosertib

BI-847325

AZD4547

Nazartinib; EGF816; NVS-816

EAI-045

Poziotinib

Osimertinib Mesylate

BEC HCl

PRT-060318; PRT318; P142–76

BAY 61-3606 2HCl

GSK2256098

Flibanserin

BAY-1895344

Verucerfont

MSC2530818

PQR530

Lanifibranor

AZD-5069

CYC-065

AstraZeneca receives regulatory boost for...

Top 7 Trends In Pharmaceutical Research I...

ARS-1620: A promising new inhibitor for K...

AstraZeneca receives regulatory boost for...

Top 7 Trends In Pharmaceutical Research I...